Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmacovigilance
Bioequivalence studies: Biowaivers
您也可能阅读
通过共同作者、期刊和引用图与本文相关的文章。
Linda J B Jeng1, Jeffrey Siegel2
1Division of Biomedical Informatics, Research, and Biomarker Development, Office of Drug Evaluation Sciences, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
美国食品和药物管理局 (FDA) 需要有力的证据表明,药物可以改善患者的福祉,功能或生存. 用作替代终点 (SE) 的生物标志物可以加快针对未满足需求的新药的开发.
科学领域:
背景情况:
研究的目的:
主要方法:
主要成果:
结论: